Khalpey, Zain http://orcid.org/0009-0006-2607-5555
Kumar, Ujjawal http://orcid.org/0000-0001-8655-5856
Hitscherich, Pamela
Aslam, Usman
Chnari, Evangelia
Long, Marc
Article History
Received: 4 March 2024
Accepted: 25 May 2024
First Online: 1 June 2024
Declarations
:
: The terms of the research have been reviewed and appropriately managed by HonorHealth per its conflict-of-interest policies and appropriate Institutional Review Board ethical approval was granted for outcome analysis in this study (IRB#20200195). Full informed consent for the surgical procedures as well as anonymized inclusion into this study was obtained for all patients. No patient-identifiable information is contained within this work. All methods of this study were conducted following the relevant guidelines and regulations for working with human subjects. The HPMAs used in this study (MTF AmnioBandĀ® Matrix, MTF Biologics, Edison, NJ) are aseptically processed amnion and chorion tissue forms regulated for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Sect.Ā 361 of the Public Health Service (PHS) Act when labelled and promoted for use in wound treatment and management as a protective covering for internal or external soft tissue defects including acute, chronic, and surgically created wounds.
: All patients were appropriately consented for retrospective outcome analysis and inclusion in this subsequent publication.
: ZK serves as a consultant for MTF Biologics. PH, EC, and ML are employed by MTF Biologics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be a potential conflict of interest.